2月5日,港股18A上市的Biotech公司圣诺医药(02257)发布了一则公告,其创始人、非执行董事陆阳因希望投入更多时间于其他事务,自当日起辞任非执行董事、董事会提名委员会成员、集团荣誉首席科学官及授权代表职务。不过,陆阳并未完全与圣诺医药“切割”,获委任为集团荣誉科学顾问。消息一出,市场目光再度聚焦这家曾有“中国核酸药物第一股”光环的企业。早在2024年12月23日,陆阳就已提出请求并获准...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.